Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Oncofetal Antigen

  • Peter L. Stern
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_4219-2


Oncofetal genes are those that are expressed in developing (fetal) as well as cancer (onco) cells. This expression can reflect shared functions important during development and which are reactivated, during neoplasia. Sometimes the latter can involve functional changes which may be delivered through structural modifications (e.g., amino acid sequence change) or by the levels or context of the expression (altered or different gene promoters of transcription). The term antigen relates to the property of the gene product and/or its added posttranslational modifications (e.g., glycosylation) which can be recognized by the immune system (e.g., antibodies). Most self molecules are non-immunogenic and not able to induce antibodies in the same organism which are said to be tolerant. Often oncofetal antigens are immunogenic since they are not expressed widely in the adult animals and the immune system is not tolerant and they can elicit self immunity under some circumstances.



Smallpox Vaccine Oncofetal Antigen Amino Acid Sequence Change Cellular Mediate Immunity Negative Growth Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Dermime S, Gilham DE, Shaw DM et al (2004) Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta 1704:11–35PubMedGoogle Scholar
  2. Mizejewski GJ (2001) Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med 226:377–408Google Scholar
  3. Stern PL (2015) Immunotherapies Targeting a Tumor-Associated Antigen, 5T4 Oncofetal Glycoprotein. In: Cancer Immunology: Bench to Bedside Immunotherapy of Cancers Ed. Rezaei N Springer Berlin Heidelberg pp 409–425Google Scholar
  4. Thistlethwaite F, Mansoor W, Gilham DE et al (2005) Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy. Curr Opin Mol Ther 7:48–55PubMedGoogle Scholar
  5. Zbar AP (2004) The immunology of colorectal cancer. Surg Oncol 13:45–53CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Paterson Building, Institute of Cancer SciencesUniversity of ManchesterManchesterUK